Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed. Stock Photo

RMID:PJ7073

Image details

Contributor:

PA Images / Alamy Stock Photo

Image ID:

PJ7073

File size:

23.4 MB (857.3 KB Compressed download)

Releases:

Model - no | Property - noDo I need a release?

Dimensions:

2333 x 3500 px | 19.8 x 29.6 cm | 7.8 x 11.7 inches | 300dpi

Date taken:

4 September 2018

Photographer:

More information:

This image could have imperfections as it’s either historical or reportage.

Available for editorial and personal use only. Get in touch for commercial uses.

Search stock photos by tags

18 month course patisiran condition career saved by carlos heras-palou 53 destroyed nerves halted hands health hereditary transthyretin-mediated amyloidosis hattr amyloidosis however after may new drug called patisiran orthopaedic specialist surgeon derby nuffield hospital progressed rare disease rendering them useless reversed surgeon

Similar stock images

RMPJ4GK7–Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ4GH0–Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ706T–Carlos Heras-Palou, 53, performing hand surgery at Derby Nuffield Hospital. Mr Heras-Palou, an orthopaedic specialist surgeon, may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ4GKH–Carlos Heras-Palou, 53, performing hand surgery at Derby Nuffield Hospital. Mr Heras-Palou, an orthopaedic specialist surgeon, may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ4GH4–Embargoed to 0001 Wednesday September 5 Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ4GK0–Embargoed to 0001 Wednesday September 5 Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ4GHA–Embargoed to 0001 Wednesday September 5 Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ4GKB–Embargoed to 0001 Wednesday September 5 Carlos Heras-Palou, 53, performing hand surgery at Derby Nuffield Hospital. Mr Heras-Palou, an orthopaedic specialist surgeon, may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ7072–Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ7078–Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ7084–Carlos Heras-Palou 53, an orthopaedic specialist surgeon at Derby Nuffield Hospital, who may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.

RMPJ7075–Carlos Heras-Palou, 53, performing hand surgery at Derby Nuffield Hospital. Mr Heras-Palou, an orthopaedic specialist surgeon, may have had his career saved by a new drug called 'Patisiran'. The rare disease, hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), progressed and destroyed the nerves in his hands, rendering them useless. However after an 18 month course of Patisiran the condition has halted and reversed.